The present study was aimed to investigate the behavioral and molecular effects of lamotrigine. To this aim, Wistar rats were treated with lamotrigine (10 and 20 mg/kg) or imipramine (30 mg/kg) acutely and chronically. The behavior was assessed using forced swimming test. Brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), Proteina Kinase B (PKB, AKT), glycogen synthase kinase 3 (GSK-3) and B-cell lymphoma 2 (Bcl-2) levels, citrate synthase, creatine kinase and mitochondrial chain (I, II, II-III and IV) activities were assessed in the brain. The results showed that both treatments reduced the immobility time. The BDNF were increased in the prefrontal after acute treatment with lamotrigine (20 mg/kg), and the BDNF and NGF were increased in the prefrontal after chronic treatment with lamotrigine in all doses. The AKT increased and Bcl-2 and GSK-3 decreased after both treatments in all brain areas. The citrate synthase and creatine kinase increased in the amygdala after acute treatment with imipramine. Chronic treatment with imipramine and lamotrigine (10 mg/kg) increased the creatine kinase in the hippocampus. The complex I was reduced and the complex II, II-III and IV were increased, but related with treatment and brain area. In conclusion, lamotrigine exerted antidepressant-like, which can be attributed to its effects on pathways related to depression, such as neurotrophins, metabolism energy and signaling cascade.
Introduction
Depression is a severe disorder that has enormous consequences for the individual's quality of life, and it is among the most prevalent forms of mental illness. Clinical symptoms like depressed mood, anhedonia, fatigue or loss of energy, feelings of worthlessness or guilt, and the diminished ability to concentrate or think are characteristics of depression. Despite the devastating impact of depression, relatively little is known about the etiology and pathogenesis of depression (Larsen et al., 2010) .
Lamotrigine is an anticonvulsant drug that has shown efficacy in the treatment of bipolar depression and resistant major depressive episodes Calabrese et al., 1999; Frye et al., 2000; Barbosa et al., 2003) . However, the mechanism of antidepressant action of lamotrigine is still unclear. Although the blockade of neuronal voltage-dependent sodium channels elicited by lamotrigine has an important role in its anticonvulsant effect, and it shares a common action with other mood stabilizing anticonvulsants, the antiglutamatergic effect of lamotrigine has been implicated in its mood effect (Ketter et al., 2003) . In addition to these effects, lamotrigine also blocks neuronal voltage-dependent calcium channels (Ketter et al., 2003) Moreover, the reduction of glutamate release induced by lamotrigine may be related to the blockade of neuronal voltage-dependent sodium and calcium channels (Ketter et al., 2003) . Reduced glutamatergic neurotransmission has been related to an antidepressant effect. For example, antagonists of the N-methyl-D-aspartate (NMDA) complex exhibit an antidepressant-like effect in animal models of depression (Paul and Skolnick, 2003; Réus et al., 2010 Réus et al., , 2011 . Moreover the lamotrigine presents effects in dopaminergic, adrenergic, muscarinic, opioid, adenosine, serotonin (5HT3) and 5HT1A receptors (for a review see: Goldsmith et al., 2003) .
Evidence indicates that neurotrophins such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) may play a role in the pathophysiology of depression and that antidepressants may in part exert their effects through the regulation of BDNF and NGF. Several clinical studies have reported that serum BDNF levels are decreased in depressed patients, and that they can be normalized by antidepressant treatment (Brunoni et al., 2008; Gervasoni et al., 2005) .
The understanding of the signaling pathways in neurons or the investigation of new components with already discovered ones can be considered as the basis to finding molecular-biological causes of neuropsychiatric diseases (D'Sa and Duman, 2002) . Protein Kinase B (PKB, AKT), glycogen synthase kinase 3 (GSK-3) and components regulating programmed cell death, especially the family of B-cell lymphoma 2 (Bcl-2) proteins and various mitochondrial factors, are intensively studied because of the known biochemical effects of the long-term administration of antidepressants and mood stabilizers, with regard to the supposed role of the survival, plasticity and metabolism of neurons during mental and neurodegenerative diseases (Jope and Roh, 2006) . Recently, it has been proposed that antidepressants may exert their long-term therapeutic effects by triggering cellular mechanisms that promote neuronal plasticity and neuroprotective pathways by increasing the neurogenesis in the hippocampus (Malberg et al., 2000) .
Most cellular energy is obtained through oxidative phosphorylation, a process requiring the action of various respiratory enzyme complexes located in a special structure of the inner mitochondrial membrane, the mitochondrial respiratory chain. It is well described that mitochondrial dysfunction has been implicated in the pathogenesis of a number of diseases affecting the brain, such as dementia, cerebral ischemia, Alzheimer's disease and Parkinson's disease (Blass, 2001; Brennan et al., 1985; Heales et al., 1999; Schurr, 2002; Monsalve et al., 2007) . Several recent works also support the hypothesis that metabolism impairment is involved in the pathophysiology of depression (Tretter et al., 2007; Petrosillo et al., 2008; Kanarik et al., 2008; Stanyer et al., 2008) .The enzyme creatine kinase (CK), catalyses the reversible transphosphorylation of creatine by adenosine triphosphate and plays a key role in energy buffering and energy transport, particularly in cells with high and fluctuating energy requirements, including neurons (Andres et al., 2008) . It is also known that a diminution of CK activity may potentially impair energy homeostasis, contributing to cell death (Aksenov et al., 2000; David et al., 1998) In addition, citrate synthase has been used as a quantitative enzyme marker for the presence of intact mitochondria (Marco et al., 1974) , which may be related with mood disorders (Agostinho et al., 2009) .
Therefore, considering that neutrophins, energy metabolism and cell signaling cascades are all involved in the pathophysiology of mood disorders and that there are still no studies showing the consistent effects of lamotrigine on these targets, the present study was aimed to investigate the behavioral and physiological effects of acute and chronic administration of lamotrigine in rats. The behavioral effects were evaluated in the open field and forced swimming tests. Additionally, creatine kinase citrate, synthase activities and mitochondrial respiratory chain (I, II, II-III and IV) activities; Bcl-2, AKT and Gsk-3 expression; and BDNF and NGF protein levels were assessed in the prefrontal cortex, hippocampus and amygdala.
Material and methods

Animals
Male Adult Wistar rats (60 days old) were obtained from the breeding colony at UNESC (Universidade do Extremo Sul Catarinense, Criciúma, SC, Brazil). They were housed five per cage with food and water available ad libitum and were maintained on a 12-h light/dark cycle (lights on at 7:00 a.m.). All experimental procedures involving animals were performed in accordance with the NIH Guide for the Care and Usage of Laboratory Animals and under the Brazilian Society for Neuroscience and Behavior (SBNeC) recommendations for animal care, and with approval by the local Ethics Committee under protocol number 01/2011.
Drugs and treatments
Lamotrigine was purchased from Sigma (Brazil) and imipramine, a classic antidepressant was purchased from Novartis Pharmaceutical Industry (São Paulo, Brazil). Different groups of rats (n = 15 each) were administered intraperitoneally (i.p.) with saline (control group), different doses of lamotrigine (10 mg/kg and 20 mg/kg) or imipramine (30 mg/kg) (positive control) in one single dose (acute treatment) or over the course of 14 days, once a day (chronic treatment), the protocols being in accordance with previous study executed by Kaster et al. (2007) . All treatments were administered in a volume of 1 ml/kg. The behavior tests (open-field and forced swimming tests) were evaluated one hour after the administration of the last injection.
Open-field test
This apparatus consists of a 45 Â 60 cm brown plywood arena surrounded by 50 cm high wooden walls and containing a frontal glass wall. The floor of the open field was divided into nine rectangles (15 Â 20 cm each) by black lines. Animals were gently placed on the left rear quadrant and left to explore the arena. In a separate series of experiments, rats were acutely treated with lamotrigine (10 and 20 mg/kg), imipramine (30 mg/kg) and saline 60 min before exposure to the open-field apparatus and after 12 days of chronic treatment, rats were exposed to the open-field apparatus. The numbers of horizontal (crossings) and vertical (rearings) activities performed by each rat during the 5 min observation period were counted by an expert observer, in order to assess the possible effects of drug treatment on spontaneous locomotor activity.
Forced swimming test
The forced swimming test was conducted according to previous reports (Garcia et al., 2008a,b; Porsolt et al., 1977; Detke et al., 1995) . The test involves two individual exposures to a cylindrical tank filled with water, in which the rats cannot touch the bottom of the tank or escape. The tank is made of transparent Plexiglas, 80 cm tall, 30 cm in diameter, and filled with water (22-23°C) to a depth of 40 cm. For the first exposure, rats without drug treatment were placed in the water for 15 min (pre-test session). Twenty-four hours later, rats were once again placed in the water for a 5 min session (test session), and the immobility time of rats were recorded in seconds. Rats were treated with lamotrigine, imipramine or saline only 60 min before the second exposure to the cylindrical tank of water (test session). On day 13 of chronic treatment, 1 h after drug administration, the rats were individually placed in the cylinder containing water for 15 min (pre-test session). On the 14th day the rats received the last intraperitoneal drug treatment, and after 1 h they were again subjected to the forced swimming test for a 5-min session (test session). During the test session immobility time was recorded. After the behavioral tests, in both acute and chronic treatments, all rats were killed by decapitation and the skulls were immediately removed. The prefrontal cortex, hippocampus and amygdala were quickly isolated by hand dissection using a magnifying glass and a thin brush, the dissection being based on histological distinctions described by Paxinos and Watson (1986) .
Neurotrophins measurement
The BDNF and NGF levels in the prefrontal cortex, hippocampus and amygdala (n = 6-8 each) were measured by sandwich-ELISA, according to the manufacturer's instructions (Chemicon, USA for BDNF and Millipore, USA & Canada for NGF). Briefly, the rat prefrontal cortex, hippocampus and amygdala were homogenized in phosphate buffer solution (PBS) with protease inhibitor cocktail (Sigma). Microtiter plates (96-well flat-bottom) were coated for 24 h with the samples diluted 1:2 in sample diluent and the standard curve ranged from 7.8 to 500 pg/ml of BNDF and NGF. The plates were then washed four times with sample diluent and a monoclonal anti-BNDF, and an anti-NGF rabbit antibody (diluted 1:1000 in sample diluent) was added to each well and incubated for 3 h at room temperature. After washing, a peroxidase conjugated anti-rabbit antibody (diluted 1:1000) was added to each well and incubated at room temperature for 1 h. After the addition of the streptavidin-enzyme, substrate and stop solutions, the amount of each neurotrophin was determined by absorbance in 450 nm. The standard curve demonstrates a direct relationship between Optical Density (OD) and the concentration. Total protein was measured by Lowry's method using bovine serum albumin as a standard, as previously described by Lowry et al. (1951) .
Respiratory chain enzyme activities
The homogenates (n = 5 each) were centrifuged at 800g for 10 min and the supernatants kept at À70°C until used for enzyme activity determination. The maximal period between homogenate preparation and enzyme analysis was always less than 5 days. Protein content was determined by the method described by Lowry et al. (1951) using bovine serum albumin as standard. NADH dehydrogenase (complex I) was evaluated by the method described by Cassina and Radi (1996) by the rate of NADH-dependent ferricyanide reduction at 420 nm. The activity of succinate: Cytochrome c oxidoreductase (complexes II and II-III) were determined according to the method of Fischer et al, measured by Cytochrome c reduction from succinate. The activity of Cytochrome c oxidase (complex IV) was assayed according to the method described by Rustin et al, measured by following the decrease in absorbance due to the oxidation of previously reduced Cytochrome c at 550 nm with 580 nm as reference wavelength (e = 19.1 mM À1 cm
À1
). The reaction buffer contained 10 mM potassium phosphate, pH 7.0, 0.6 mM n-dodecyl-Dmaltoside, 2-4 l g À1 homogenate protein and the reaction was initiated with addition of 0.7 l g À1 reduced cytochrome c. The activity of complex IV was measured at 25°C for 10 min. The activities of the mitochondrial respiratory chain complexes were described as nmol min À1 mg protein
.
Creatine kinase activity
The homogenates (n = 5 each) were centrifuged at 800g for 10 min. and the supernatants kept at À70°C until used for creatine kinase activity determination. The maximal period between homogenate preparation and enzyme analysis was always less than 5 days. Protein content was determined by the method described by Lowry et al. (1951) using bovine serum albumin as standard. Creatine kinase activity was measured in brain homogenates pre-treated with 0.625 mM lauryl maltoside. The reaction mixture consisted of 60 mM Tris-HCl, pH 7.5, containing 7 mM phosphocreatine, 9 mM MgSO 4 and approximately 0.4-1.2 lg protein in a final volume of 100 lL. After 15 min of preincubation at 37°C, the reaction was started by the addition of 0.3 lmol of ADP plus 0.08 lmol of reduced glutathione. The reaction was stopped after 10 min by the addition of 1 lmol of hydroxymercuribenzoic acid. The creatine formed was estimated according to the colorimetric method of Hughes (1962) . The color was developed by the addition of 100 lL 2% a-naphthol and 100 lL 0.05% diacetyl in a final volume of 1 mL and read spectrophotometrically after 20 min at 540 nm. Results were described as nmol min À1 mg protein
À1
Citrate synthase activity
The prefrontal cortex, hippocampus and amygdala (n = 5 each) were homogenized (1:10, w/v) in SETH buffer (0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCl, pH 7.4). The homogenates were centrifuged at 800Âg for 10 min and the supernatants were kept at À70°C until it will be used for enzyme activity determination. Protein content was determined by the method described by Lowry et al. (1951) using bovine serum albumin as standard. Citrate synthase activity was assayed according to the method described by Shepherd and Garland (1969) . The reaction mixture contained 100 mM Tris, pH 8.0, 100 mM acetyl CoA, 100 mM 5,5-di-thiobis (2-nitrobenzoic acid), 0.1% triton X-100, and 2-4 g supernatant protein and was initiated with 100 Moxaloacetate and monitored at 412 nm for 3 min at 25°C (the final volume of reaction mixture was 0.3 mL).
Protein analysis by immunoblotting
The Prefrontal cortex, hippocampus and amygdala tissues (n = 5 each) were excised. The tissues were homogenized immediately in extraction buffer (mM) (1% Triton-X 100, 100 Tris, pH 7.4, containing 100 sodium pyrophosphate, 100 sodium fluoride, 10 EDTA, 10 sodium vanadate, 2 PMSF and 0.1 mg of aprotinin/ml) at 4°C with a Polytron PTA 20S generator (Brinkmann Instruments model PT 10/35) operated at maximum speed for 30 s. The extracts were centrifuged at 11,000 rpm and 4°C in a Beckman 70.1 Ti rotor (Palo Alto, CA) for 40 min to remove insoluble material, and the supernatants of these tissues were used for protein quantification, using the Bradford method. Proteins were denatured by boiling in (Laemmli, 1970) sample buffer containing 100 mM DTT (De Souza et al., 2003) . After this, 0.2 mg of protein extracts obtained from each tissue were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted with anti-AKT, anti-Bcl-2 and anti-GSK-3b. Antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Chemiluminescent detection was performed with horseradish peroxidase-conjugate secondary antibodies. Visualization of the protein bands was performed by exposure of the membranes to RX-films. The original membrane was stripped and reblotted with actin loading protein (bands not showing). After transfer, the membrane was stained with Ponceau and bands were visualized, photographed and quantified before the primary antibody, to control the transfer. Band intensities were quantitated by optical densitometry (Scion Image software, ScionCorp, Frederick, MD) of the developed autoradiographs.
Statistical analysis
All data are presented as mean ± SEM. Differences among experimental groups in the forced swimming and open field tests and in the assessment of the biochemical analysis were determined by one-way ANOVA, followed by Tukey post-hoc test when ANOVA was significant; P values <0.05 were considered to be statistically significant.
Results
The effects of the acute and chronic administration of lamotrigine on the immobility times are illustrated in Fig. 1A . In the acute (F (3-21) = 6.148; p = 0.04 Fig. 1A ) and chronic (F (3-66) = 6.222; p = 0.01 Fig. 1A ) treatments we observed a decrease in the immobility time with imipramine at the dose of 30 mg/kg and lamotrigine at the doses of 10 and 20 mg/kg, compared with saline.
Interestingly, in the open-field test both acute and chronic treatments with imipramine or lamotrigine did not modify the number of crossings (acute; F (3-55) = 0.595; p = 0.62; Fig. 1B With regards to the acute treatment, there was an increase the BDNF levels in the prefrontal cortex with lamotrigine at the dose of 20 mg/kg (F (3-16) = 5.501; p = 0,009 Fig. 2A ), compared with saline, but BDNF protein levels did not alter in the prefrontal cortex with imipramine at the dose of 30 mg/kg (F (3-16) = 5.501; p = 0.22 Fig. 2A ) and with lamotrigine at the dose of 10 mg/kg (F (3-16) = 5.501; p = 0.91 Fig. 2A ), compared with saline. The amygdala (F (3-16) = 1.292; p = 0,31 Fig. 2A ) and the hippocampus (F (3-16) = 2.844; p = 0.71 Fig. 2A ) did not have any alterations in their BDNF levels after acute treatment. In the chronic treatment data, we found an increase occurred in the BDNF levels in the prefrontal cortex with lamotrigine at the dose of 10 and 20 mg/kg (F (3-16) = 8.478; p = 0.01 Fig. 2A ), compared with saline, but BDNF protein levels did not alter in the prefrontal cortex with imipramine (F (3-16) = 8.478; p = 0.62 Fig. 2A ), compared with saline. In the amygdala (F (3-16) = 2.676; p = 0.82; Fig. 3B ) and in the hippocampus (F (3-16) = 1.693; p = 0.20; Fig. 2A ), there were no alterations in the BDNF levels after chronic treatment.
The acute treatment did not alter the NGF protein levels in the prefrontal cortex (F (3-16) = 1.024; p = 0.40 Fig. 2B ), in the amygdala (F (3-16) = 3.076; p = 0.58 Fig. 2B ) or in the hippocampus (F (3-16) = 0.095; p = 0.96 Fig. 2B ). The chronic treatment increased the NGF levels in the prefrontal cortex with lamotrigine at the dose of 10 and 20 mg/kg (F (3-15) = 8.982; p = 0.01 Fig. 2B ), compared with saline, but the NGF protein levels did not alter in the prefrontal cortex with imipramine at the dose of 30 mg/kg (F (3-15) = 8.982; p = 0.57 Fig. 2B ). The amygdala (F (3-16) = 0,230; p = 0.87 Fig. 2B ) and the hippocampus (F (3-16) = 3.2080; p = 0.51 Fig. 2B ) did not have alterations in the BDNF levels after chronic treatment.
The acute treatment increased the citrate synthase activity in the amygdala with imipramine at the dose of 30 mg/kg (F (3-10) = 6.474; p = 0.02 Fig. 3A ) compared with saline. In the prefrontal cortex and hippocampus there were no alterations in the citrate synthase activity after acute treatment. The chronic treatment did not alter the citrate synthase activity in the prefrontal cortex (F (3-11) = 0.460; p = 0.71 Fig. 3A) , amygdala (F (3-12) = 2.676; p = 0.94 Fig. 3A ) or hippocampus (F (3-12) = 3.079; p = 0.68 Fig. 3A) .
The acute treatment increased the creatine kinase activity in the amygdala with imipramine at the dose of 30 mg/kg (F Fig. 4C ) with imipramine at the dose of 30 mg/kg and in the amygdala (F (3-14) = 10.512; p = 0.001 Fig. 4C ) with all treatments, but did not alter in the prefrontal cortex (F (3-15) = 4.175; p > 0.05 Fig. 4C ) and in the hippocampus (F (3-13) = 10.168; p > 0.05 Fig. 4C ). The acute administration increased the mitochondrial complex IV activity in the hippocampus (F (3-13) = 18.471; p < 0,001 Fig. 4D ) with all treatments, compared with saline, but did not alter in the prefrontal cortex (F (3-12) = 0.828; p = 0.50 Fig. 4D ) and amygdala (F (3-11) = 4,514; p = 0,27 Fig. 4D ). The chronic treatment did not alter the mitochondrial complex IV activity in the prefrontal cortex (F (3-13) = 0.689; p = 0.57 Fig. 4D ), amygdala (F (3-16) = 3.666; p = 0.35 Fig. 4D ) or hippocampus (F (3-11) = 2.317; p = 0.13 Fig. 4D ).
The acute treatment decreased the Bcl-2 protein levels in the prefrontal cortex (F (3-12) = 106.818; p < 0,001 Fig. 5A ) and in the hippocampus (F (3-12) = 265,226; p < 0,001 Fig. 5A ) with imipramine at the dose of 30 mg/kg and lamotrigine at the dose of 20 mg/kg, and also in the amygdala (F (3-12) = 87.304; p < 0.001 Fig. 5A ) with all treatments, compared with saline. The chronic treatment decreased the Bcl-2 protein levels in the prefrontal cortex (F (3-12) = 310.093; p < 0.001 Fig. 5A ), amygdala (F (3-12) = 238.818; p < 0.001 Fig. 5A ) and hippocampus (F (3-12) = 557.669; p < 0.001 Fig. 5A ) with all treatments. The effects of administration of acute and chronic does of lamotrigine and imipramine on the BDNF protein levels (A) and NGF protein levels (B) in the prefrontal cortex, hippocampus and amygdala. Bars represent means ± S.E.M. (n = 6-8). ⁄ P < 0.05 compared to saline group according to ANOVA followed by Tukey post-hoc test.
The acute treatment increased the AKT protein levels in the prefrontal cortex (F (3-12) = 49.088; p = 0.000 Fig. 5B ) with imipramine at the dose of 30 mg/kg, in the amygdala (F (3-12) = 70.335; p < 0.001 Fig. 5B ) with lamotrigine at the dose of 20 mg/kg and in the hippocampus (F (3-12) = 21.011; p = 0.009 Fig. 5B) , with imipramine at the dose of 30 mg/kg and with lamotrigine at the dose of 20 mg/kg, compared with saline. The acute treatment also decreased the AKT protein levels in the amygdala with imipramine at the dose of 30 mg/kg (F (3-12) = 70.335; p = 0.04 Fig. 5B ) and in the hippocampus with lamotrigine at the dose of 10 mg/kg (F (3-12) = 21.011; p = 0.04 Fig. 5B ). The chronic treatment increased the AKT protein levels in the prefrontal cortex (F (3-12) = 121.938; p < 0,001 Fig. 5B ), amygdala (F (3-12) = 83.853; p < 0.001 Fig. 5A ) and hippocampus (F (3-12) = 58.262; p < 0,001 Fig. 5B ) after all treatments.
The acute treatment decreased the GSK-3 protein levels in the prefrontal cortex with imipramine at the dose of 30 mg/kg and lamotrigine at the dose of 20 mg/kg (F (3-12) = 126.185; p < 0.001 Fig. 5C ), compared with saline. In the amygdala (F (3-12) = 328.079; p < 0.001 Fig. 5C ) the GSK-3 protein levels decreased with all doses, and in the hippocampus with imipramine at the dose of 30 mg/kg (F (3-12) = 80.214; p < 0.001 Fig. 5C ) after acute treatment, compared with saline. The chronic treatment decreased the GSK-3 protein levels in the prefrontal cortex (F (3-12) = 168.217; p = 0.001 Fig. 5C ) and in the amygdala (F (3-12) = 535.095; p < 0.001 Fig. 5C ) with all doses, and in the hippocampus (F (3-12) = 596.903; p < 0.001 Fig. 5C ) with imipramine at the dose of 30 mg/kg and lamotrigine at the dose of 20 mg/kg.
Discussion
Depression is a clinically and biologically heterogeneous disease, with 10-30% of women and 7-15% of men likely to suffer from depression in their life-time (Briley and Moret, 2000) . However, combinations of multiple genetic factors may be involved in the development of depression, because a defect in a single gene usually fails to induce the expression of multifaceted symptoms of depression (Larsen et al., 2010) . Also, various non-genetic factors such as stress, affective trauma, viral infection, and neurodevelopmental abnormalities increase the complexity of the pathogenesis of the disease. Thus, extensive studies have led to a variety of hypotheses for the molecular mechanism of depression, but a definite pathogenic mechanism has yet to be defined.
The behavioral effects induced by imipramine in rats reported in the present study are in agreement with literature data, which support an antidepressant action for imipramine in basic and clinical studies. In fact, findings from our group have demonstrated that a single injection of imipramine (10 and 20 mg/kg) and chronic administration of imipramine (10, 20 and 30 mg/kg) decreased the immobility time of rats in the forced swimming test, without modifying the locomotor activity (Garcia et al., 2008a,b) . Our results showed that acute and chronic treatment with lamotrigine decreased the immobility time of rats in the forced swimming test, without changing locomotor activity in open field test compared to saline. Consistent with our study, Consoni et al. (2006) showed that lamotrigine (10 mg/kg) decreased immobility and increased climbing scores, a similar pattern to nortriptyline, in addition, lamotrigine neither changed locomotion in the open-field test nor impaired habituation. Kaster et al. (2007) also showed that lamotrigine (20-30 mg/kg) decreased the immobility time in the forced swimming test. Still, Mikulecká et al. (2004) showed that administration of lamotrigine (10 and/or 20 mg/kg for 6 consecutive days) did not change motor abilities and behavior in an open field. However, recently Barbee et al. (2011) in a double-blind placebo-controlled evaluating patients with treatment-resistent depression showed that there was no difference between lamotrigine and placebo groups. The authors suggesting that lamotrigine's efficacy might focus on specific subgroups with depression. The precise molecular mechanisms responsible for the antidepressant action of lamotrigine are still not fully understood. Indeed studies have suggested that Antiepileptic drugs, such as lamotrigine presents targets of action in the synapse, which could be relevant in epilepsy and other disorders. The mechanisms of action including, modulating ion channels and receptors and intracellular signaling pathways (Johannessen, 2008; Mazza et al., 2007) . Interestingly, evidence suggests that a variety of intracellular pathways and signal transduction cascades are involved in both the pathophysiology and treatment of depression (Coyle and Duman, 2003; Duman, 1998; Duman et al., 1997; Vaidya et al., 2007) . Many antidepressant drugs acutely increase monoamine levels, but the requirement for chronic treatment has led to the hypothesis that long-term adaptations are necessary for the therapeutic actions of these treatments (Duman et al., 1994) . Among the many long term targets of antidepressant treatments may be the regulation of neurotrophins, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).
Our results showed that the acute and chronic treatments with lamotrigine increased the BDNF levels in the prefrontal cortex. Consistent with this result, Li et al. (2010) showed that the chronic treatment with lamotrigine (30 mg/kg) increased BDNF protein expression in the prefrontal cortex, but contrarily to our result the BDNF protein expression was also increased in the hippocampus. We cannot explain why such discrepancies occur, but they may be related to the dosage used. In addition, a study by our group showed that acute administration of ketamine at the higher dose 15 mg/kg, but not in lower doses, increased BDNF protein levels in the rat hippocampus. Our results also showed that chronic, but not acute; treatment with lamotrigine increased the NGF levels in the prefrontal cortex. Another result showed that in rats, treatment with lithium at various dosages increased NGF in the hippocampus, amygdala, frontal cortex, and limbic forebrain, whereas NGF in the striatum, midbrain, and hypothalamus was unchanged (Hellweg et al., 2002) . Our results showed that imipramine did not alter de BDNF and NGF levels, suggesting that the antidepressant effects of lamotrigine may be related, at least in part, by its action on the neurotrophins, which was not observed with the classic antidepressant.
It is important that others studies have been shown effects of imipramine on the BDNF. In fact, chronic treatment with imipramine increased BDNF mRNA levels in the dentate gyrus of the dorsal hippocampus (Larsen et al., 2010) . Réus et al. (2011) also pointed to increase on the BDNF levels with imipramine in the prefrontal cortex, hippocampus and amygdala by imunoblot, its effects were more pronounced when co-administrated with ketamine, an antagonist of NMDA receptor. In contrast, others no have been shown effects of imipramine on the BDNF levels in the hippocampus (Garcia et al., 2008a,b; Fortunato et al., 2010) , suggesting that imipramine presents effects on the BDNF related with brain area and technical used.
There is a strong body of evidence suggesting that dysfunction in brain metabolism is related to neuropsychiatry disorders, such as, depression and bipolar disorder (Albert et al., 2002; Kato and Kato, 2000; Konradi et al., 2004) . Our findings showed that imipramine increased the citrate synthase activity in the amygdala after acute treatment, but not in the chronic treatment. In fact, a previous study already showed that the acute administration (but not chronic), with antipsychotic olanzapine and antidepressant fluoxetine increased citrate synthase activity in the brain areas (Agostinho et al., 2009) , suggesting that the results could be related to desensitization to the effects of the repeated administration of drugs, or to an adaptation mechanism.
Considering that metabolism impairment is probably involved in the pathophysiology of depressive disorders, an increase in creatine kinase activity by antidepressants may be an important mechanism of action of these drugs. In the present work we showed that CK was increased in the amygdala after the administration of imipramine in the acute treatment and in the hippocampus after the administration of imipramine and lamotrigine in the chronic treatment. Another study showed that CK activity was increased after the chronic administration of paroxetine . Assis et al. (2009) also reported that the acute administration of ketamine and imipramine increased creatine kinase activity in the rat brain. On the other hand, the chronic administration of nortriptiline and venlafaxine did not affect CK activity in the rat brain . Some other studies also point to the possibility that drugs used in the treatment of such disorders modulate energy metabolism Gamaro et al., 2003; Streck et al., 2006) . Studies have reported brain energy metabolism impairment in an animal model of mania induced by amphetamine. It has been demonstrated that the administration of amphetamine inhibited citrate synthase (Corrêa et al., 2007) and creatine kinase (Streck et al., 2008) activity in the brain of rats. Thus, it is possible that diminution of brain energy metabolism is involved in the pathophysiology of psychiatric disorders (Fattal et al., 2006; Madrigal et al., 2001) .
In this context, Gardner et al. (2003) showed a significant decrease of mitochondrial ATP production rates and mitochondrial enzyme ratios in muscle in major depressive disorder patients, when compared to controls. In the present study we demonstrated that both acute and chronic treatments with imipramine or lamotrigine altered respiratory chain complexes in rat brain, however these alterations were different with relation to protocols (acute or chronic), complex and brain area.
Furthermore, study from our group also showed that mitochondrial respiratory chain complexes I, III and IV were inhibited after chronic mild stress in the cerebral cortex and cerebellum, and acute administration of ketamine reversed this inhibition ). Madrigal et al. (2001 also reported that complexes I-III and II-III of mitochondrial respiratory chain were inhibited in rat brain after chronic stress (immobilization for six hours over 21 days). Additionally, Ben-Shachar and Karry (2008) demonstrated reductions in mRNA and protein of complex I subunits NDUFV1, NDUFV2 and NADUFS1 in the postmortem cerebellum from patients with depression. Hroudova and Fisar (2010) using an in vitro study from pig brain, demonstrated that the complex I, II and IV activity decreased with antidepressants and mood stabilizers, suggesting in this study that antidepressants generally act as inhibitors of electron transport chain. Our findings also showed an inhibitory effect on the activity of complex I, but contrarily to this, lamotrigine and imipramine increased the activities of complexes II, II-III and IV, suggesting that the increase in the complexes II, II-III and IV activity may be related, at least in part to compensating the decrease of complex I activity. Such, the effects of lamotrigine and imipramine on the mitochondrial respiratory chain could be positive, taking into account that there is impairment in energy metabolism related to depression (Ben-Shachar and Karry, 2008; Rezin et al., 2009; Madrigal et al., 2001) .
A balance between cell death and cell proliferation must be maintained to ensure the health of every human being. Recent findings indicate that approximately one-half of all major human diseases are a consequence of abnormal apoptosis (Reed, 2002) . Neurodegeneration mediated by apoptosis can be initiated by Bax translocation from the cytosol to the mitochondria, where it affects membrane permeability and permits cytochrome c release and subsequent activation of caspases (Yang et al., 1995; Ghribi et al., 2001) . Inappropriate apoptosis can cause autoimmune and neurodegenerative disorders, as well as heart disease, while resistance to apoptosis can promote cancer and impede the effectiveness of cancer therapeutics. Our results demonstrate that imipramine and lamotrigine decreased the Bcl-2 expression in the prefrontal cortex, amygdala and hippocampus in the acute and chronic treatments. Peng et al. (2008) showed that 3 lM imipramine treatment significantly up-regulated the mRNA and protein expression and Bcl-2 in day-7 imipramine-treated neural stem cells (NSCs). Huang et al. (2007) also showed that desipramine increased the Bcl-2 expression in day 3 DP-treated NSCs. Another study demonstrated that by the fourteenth day, (but not acute treatment with citalopram), imipramine and amitriptyline in mice had significantly elevated the hippocampal Bcl-2 protein expression as compared to vehicle treated animals. (Murray and Hutson, 2007) , suggested that their elevation reflects a compensatory mechanism. Consistent with our results, another study showed a significant decrease of antiapoptotic Bcl-2 protein upon fluoxetine treatment, which is a known molecular event in the initiation of apoptosis, suggesting that the effects of fluoxetine over antiapoptotic Bcl-2 may be interpreted as activation of apoptotic response.
GSK-3 (isoform b) is an important regulator of glycogen synthesis, gene transcription, synaptic plasticity, apoptosis (cell death), cellular structure and resilience. It has been suggested that GSK-3 regulates behavior by affecting b-catenin, glutamate receptors, circadian rhythms, and serotonergic neurotransmission (Beaulieu et al., 2008) . All of these have been implicated in the pathophysiology of severe mood disorders. Our results showed a decreased in the prefrontal cortex, amygdala and hippocampus with imipramine and lamotrigine in the acute and chronic treatments. Another study showed that lithium induces neurotrophic and neuroprotective effects in rodents, partly due to GSK-3b inhibition (Gould and Manji, 2005) . Li et al. (2004) also showed that treatment with monoamine reuptake inhibitors fluoxetine and imipramine also increased the level of Gsk-3. Valproate was initially reported to inhibit GSK-3b activity in SH-SY5Y cells (Chen et al., 1999; Chuang, 2005) , but these effects have not been confirmed in neuronal cells (Gurvich and Klein, 2002) . In general, increased activity of GSK-3 is proapoptotic, whereas inhibiting GSK-3 prevents apoptosis. Thus, we suggest that in our study the effects of lamotrigine and imipramine were antiapototic, since both inhibited GSK-3.
Accumulating evidence suggests that impaired AKT and/or ERK signaling contributes to the pathogenesis of schizophrenia, bipolar disorder and major depression and pharmacological studies indicate that antipsychotics activate these signaling pathways in vivo or in vitro (Arguello and Gogos, 2008; Beaulieu et al., 2006; Lu et al., 2004; Zhang et al., 2005) . Previous reports have demonstrated that AKT is not only involved in cell growth but is also involved in glucose metabolism/uptake (Hajduch et al., 2001; Lawlor and Alessi, 2001) . AKT was shown to be a key mediator of the signal transduction process and mediates many of the survival signals (Brunet et al., 2001 ). The present study showed an increase in the prefrontal cortex with imipramine and in the amygdala and hippocampus with lamotrigine in the acute treatments. On the other hand, our data also showed decreases in the amygdala with imipramine, and in the hippocampus with lamotrigine in the acute treatment. This effect could be alternatively explained by its capacity to upregulate gene expression through inhibiting histone-deacetylase, as has been reported (Harwood and Agam 2003; De Sarno et al., 2002) . Aubry et al. (2009) showed that lithium, valproate, olanzapine and clozapine enhance proliferation and protect cells against serum withdrawal-induced injury. These drugs also activated AKT-1 and GSK-3b phosphorylation (Aubry et al., 2009) . Interestingly, gene expression of AKT-1 mRNA and protein, but not GSK-3b, was increased. Another study showed that sertraline potently inhibited the phosphorylation of AKT and caused cell death. (Reed, 2002) . Lamotrigine has a potent activity dependent on ion channels (i.e., Na+ and Ca+) and could have an indirect action on signal transduction (Xie and Hagan, 1998) . Consistent with our results, lamotrigine had an indirect action on AKT protein levels. Whether lamotrigine has direct actions on these intracellular signaling molecules has not been extensively studied to date. To our knowledge, no other previous assay has tested such a complex mechanism.
Reduced glutamatergic neurotransmission has been related to the antidepressant effect of lamotrigine. In fact, electrophysiological studies in the amygdala (Wang et al., 2002) and in the striatum (Calabrese et al., 1999) showed that lamotrigine reduced excitatory post-synaptic potential mediated by glutamate, an effect reversed when exogenous glutamate was applied, findings consistent with the proposal that lamotrigine had an inhibitory action on glutamate release. Functional antagonists of the N-methyl-d-aspartate (NMDA) complex exhibit an antidepressant-like effect in animal models of depression. In adition, NMDA receptor antagonists have demonstrated alter neutrophins , and energy metabolism Assis et al., 2009) suggesting that changes are mediated by glutamate action through NMDA receptor, thus, the effects exerted by lamotrigine in these pathways, may be related, at least in part to its action on the glutamatergic system.
Conclusions
In conclusion, this is the first study that directly compares the effects of acute and chronic lamotrigine treatment depressive-like symptoms together with the effects on neurotrophins, metabolism energy, signaling cascade. The behavioral effects of lamotrigine can be attributed to its action on neurochemistry pathways related to depression. However, the results findings in the present research were in preclinical study and we suggest clinical studies evaluating serum or postmortem brain from patients with major depression and to evaluate whether lamotrigine could be a new option for this impairment disorder.
